News
Bionova Begins Construction of New Manufacturing Center
Bionova Scientific, a biologics CDMO with deep protein production, cell line development, process development and analytical expertise, has initiated construction of its new biologics manufacturing facility. Construction will be completed in approximately 10 months, with commissioning scheduled for Q3...
Clinical Trials
Moderna’s COVID-19 Vaccine Soon to Enter Phase 3 Trials as Phase 1 Shows Positive Results
Moderna, an American biotech company announced on July 14 that its COVID-19 vaccine candidate is finally going to enter the final phase on July 27 as it has shown positive results in previous human trials. Undoubtedly, this is a...
News
Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
Roche and Blueprint Medicines Corporation announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the USA, excluding Greater China*. In the US, Genentech, a member of the Roche...
News
Gilead presents additional data on investigational antiviral remdesivir to treat COVID-19 at Virtual COVID-19 Conference
Gilead Sciences Inc, announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir.
The data are being presented at the Virtual COVID-19 Conference as part...
News
Glenmark reduces price of oral antiviral FabiFlu by 27% in India
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with...
Drug Research
Biophore India gets DCGI nod to manufacture COVID drug Favipiravir API
Biophore India Pharmaceuticals, a Hyderabad-based firm, has received license from the Drug Controller General of India (DCGI) to manufacture Favipiravir, an active pharmaceutical ingredient (API), used in the finished formulation to treat mild to moderate COVID-19 cases. Besides DCGI’s...
Clinical Trials
Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies
Orgenesis Inc., a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), announces that it has entered into a Collaboration Agreement with Educell Ltd., a premier European cell therapy company....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read